Biodexa Pharmaceuticals (BDRX) Total Non-Current Liabilities (2013 - 2025)

Biodexa Pharmaceuticals has reported Total Non-Current Liabilities for 13 years, with the latest figure at $857957.2 in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 53.06% year-over-year to $857957.2 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $857957.2 (down 53.06% YoY) and the FY2025 annual result came in at $850439.2, down 53.47% from the prior year.
• Total Non-Current Liabilities declined to $857957.2 in Q4 2025 per BDRX's latest filing, from $1.2 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $2.2 million in Q2 2024 and troughed at $366139.8 in Q4 2023.
• A 5-year average of $998114.6 and a median of $846861.9 in 2021 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2021 and 2025: Total Non-Current Liabilities soared 617.48% in 2021, then slumped 53.06% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $835766.6 in 2021, then tumbled by 35.02% to $543065.8 in 2022, then slumped by 32.58% to $366139.8 in 2023, then jumped by 399.18% to $1.8 million in 2024, then plunged by 53.06% to $857957.2 in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $857957.2, $1.2 million, and $1.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.